This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Launched by ASTRAZENECA · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to gather information about how well a medication called benralizumab works for patients in China who have severe eosinophilic asthma, a type of asthma that can be difficult to manage. The study will look at patients aged 12 and older who are starting treatment with benralizumab, focusing on how quickly they respond to the medication and how well their asthma is controlled over time. It will also explore why some doctors may choose to stop or change a patient's treatment.

To participate in this study, patients need to be at least 12 years old, have a diagnosis of severe eosinophilic asthma, and have specific blood test results that show a high level of eosinophils, which are a type of white blood cell related to asthma symptoms. However, patients who are currently involved in another clinical trial, have had certain allergic reactions, or have a history of cancer cannot take part. This study is not yet recruiting participants, but it aims to provide valuable insights that could help improve asthma care in real-world settings.

Gender

ALL

Eligibility criteria

• Inclusion criteria -Patients are eligible to be included in the study only if all of the following criteria apply:
• • Patients must to be 12 years old (inclusive) at the time of signing the informed consent.
• • Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician.
• • Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent.
• • Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.
• • Exclusion criteria
• -Patients should not enter the study if any of the following exclusion criteria are fulfilled:
• • Patients currently participating in any other clinical trial.
• • Known history of allergy or reaction to any component of the study treatment formulation.
• • Malignancy of any kind.
• • Patients with prior or ongoing treatment with benralizumab.